Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSAID-based treatment regimens for diabetic macular edema
ACTRN12622000313730Phase 3Completed
- Sponsor
- Supanji Haryanto
- Start
- Jun 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in diabetic macular edema (DME) comparing Intravitreal bevacizumab plus topical diclofenac, Intravitreal ketorolac and Intravitreal bevacizumab (3 arms). Primary endpoints: Central macular thickness, Tear VEGF level and 1 more. Started Jun 2020; status: completed.
02
Drugs
bevacizumabketorolacdiclofenac
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12622000313730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000313730.